The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion.

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Eli Lilly is currently conducting clinical trials ... Chronic illness causes family conflicts and deepens depression in South Korea There is no silver lining to a long battle with illness.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... including Singapore and South Korea, showing respectable increases. Out of 49 countries tracked, 17 ...

Ever since President Donald Trump launched his campaign of raising tariffs on trading partners, his administration has ...